We are bringing the American biotech model to Poland

Pure Biologics achieves key milestone with successful completion of Phase 0 study for PBA-0405 in cancer treatment

PB004 project – first administration in a Phase 0 clinical trial

PB003G project – the FDA approval to proceed with Phase 0 clinical trial

PB004 project – the FDA approval to proceed with Phase 0 clinical trial

Pure Biologics achieves key milestone with successful completion of Phase 0 study for PBA-0405 in cancer treatment

PB004 project – first administration in a Phase 0 clinical trial

PB003G project – the FDA approval to proceed with Phase 0 clinical trial

PB004 project – the FDA approval to proceed with Phase 0 clinical trial

Therapeutic portfolio

multiQure's therapeutic portfolio comprises RNAi gene therapy, primarily targeting Huntington's disease, but also other polyglutamine diseases. Our therapy is a best-in-class solution which, unlike the therapies commonly available on the market, halts the progression of the disease rather than merely alleviating its symptoms. Our portfolio also includes immuno-oncology projects.

RNAi Technology Immuno-oncology therapies

Investors & media

multiQure is the first listed company in Poland to pursue the American biotech model. Our goal is to confirm the efficacy of our RNAi therapy in patients, and its safety profile, as quickly as possible, in order to give investors and potential partners a clear answer rather than promises.